106 related articles for article (PubMed ID: 9781211)
21. [Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology].
Bontenbal M; Nortier JW; Beex LV; Bakker P; Hupperets PS; Nooij MA; van Veelen H; Vreugdenhil G; Richel DJ; Blijham GH
Ned Tijdschr Geneeskd; 2000 May; 144(21):984-9. PubMed ID: 10858788
[TBL] [Abstract][Full Text] [Related]
22. [Drug therapy of breast carcinoma].
Dittrich C
Wien Med Wochenschr; 2000; 150(4):72-86. PubMed ID: 10829307
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
24. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
Stotter A
Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
[No Abstract] [Full Text] [Related]
25. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
[TBL] [Abstract][Full Text] [Related]
26. Evolving treatment approaches for early breast cancer.
Campos SM
Breast Cancer Res Treat; 2005; 89 Suppl 1():S1-7. PubMed ID: 15770534
[TBL] [Abstract][Full Text] [Related]
27. Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy.
Biganzoli L; Aapro M
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):137-42. PubMed ID: 15990438
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
30. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
31. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
32. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
33. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
34. [The status of hormone therapy in breast cancer in 2001?].
Boussen H; Bouaouina N; Rahal F; Benna F
Tunis Med; 2002 Jul; 80(7):359-64. PubMed ID: 12611343
[TBL] [Abstract][Full Text] [Related]
35. Primary chemotherapy or hormonotherapy for patients with breast cancer.
Brain EG; Misset JL; Rouëss J
Cancer Treat Rev; 1999 Aug; 25(4):187-97. PubMed ID: 10448127
[TBL] [Abstract][Full Text] [Related]
36. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
37. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
Goodwin PJ
J Clin Oncol; 2003 Dec; 21(24):4474-5. PubMed ID: 14610047
[No Abstract] [Full Text] [Related]
38. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
39. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
40. [Characteristics and prognostic factors of postoperative chemotherapy for female breast cancer patients under 30 years of age: a report of 129 patients].
Wang ZH; Xu BH
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):111-3. PubMed ID: 15946553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
